Can You Do Psychedelic Therapy Through Telemedicine?

What Is Psychedelic Therapy?

Psychedelic therapy combines a psychoactive medicine with a defined support framework: preparation, a guided session, and integration afterward. Conversely, taking a substance on your own is not considered psychedelic therapy. The therapeutic framework surrounding the medicine distinguishes it from recreational or unsupervised use.

The primary medicines under the psychedelic umbrella include ketamine, MDMA, LSD, DMT, and psilocybin. Each works through different pharmacological mechanisms but shares a common care model of preparation, experience, and integration. Ketamine is pharmacologically classified as a dissociative anesthetic rather than a classic psychedelic, but many providers widely group it under the psychedelic therapy umbrella because of its similar treatment framework, altered state, and neuroplasticity-promoting effects.

Ketamine and similar medicines are not new or experimental compounds in medical practice. Ketamine has been FDA-approved as an anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.^2,3

Some of these medicines can be legally prescribed and taken at home under professional supervision. Others require in-person administration in specific settings.

• Ketamine: A dissociative anesthetic with well-established neuroplasticity-promoting effects, used off-label for depression, anxiety, and PTSD.
• MDMA: An empathogen studied primarily for PTSD in research trial settings.
• Psilocybin: A classic psychedelic under investigation for depression, with regulated access in select U.S. states.
• LSD: A classic psychedelic currently restricted to research trial settings for conditions like anxiety and depression.
• DMT: A rapid-acting classic psychedelic being researched in medical trials for major depressive disorder.

Which Conditions Can Psychedelic Therapy Treat?

Psychedelic therapy is being studied and applied across several mental health conditions. The strongest evidence base exists for depression, anxiety disorders, and PTSD.

Ketamine has the deepest real-world evidence base for treatment. Research supports its use for both treatment-resistant and moderate-to-severe presentations of depression.⁶ Studies also support ketamine's anxiolytic effects for anxiety disorders.

For PTSD, both ketamine research and the MDMA trial program show meaningful symptom reduction. Research is expanding into additional areas including addiction, OCD, grief, and burnout. Evidence strength varies by indication.

• Depression: The most extensively studied indication for ketamine therapy, with peer-reviewed real-world outcomes data behind it. Research supports its use for both treatment-resistant and moderate-to-severe presentations, and ketamine's neuroplasticity-promoting effects are the leading explanation for why improvement can appear within hours or days.
• Anxiety disorders: Anxiety frequently co-occurs with depression, and ketamine's anxiolytic effects are supported by peer-reviewed evidence. Classic psychedelics are being studied here as well: a single dose of LSD (MM120) recently earned FDA breakthrough therapy designation for generalized anxiety disorder.
• PTSD: A condition with some of the highest treatment-resistance and dropout rates in psychiatry, which makes its response to these therapies notable. Ketamine and MDMA-assisted therapy both target PTSD through different mechanisms, and both have produced meaningful symptom reduction in published research.
• Addiction: The pattern-disrupting, neuroplasticity-promoting mechanism shared across these medicines is the rationale for studying them in substance use disorders. Psilocybin has been investigated for alcohol use disorder, and ketamine for alcohol and other substance use disorders, in controlled trials.
• Expanding areas: OCD, prolonged grief, chronic pain, and burnout are active areas of investigation. Evidence strength varies widely by indication, from early-stage exploration to larger controlled trials

The conditions most relevant to telemedicine access today are depression, anxiety, and PTSD. Ketamine can be prescribed and administered at home under professional supervision for these specific indications.

Does Psychedelic Therapy Work? What the Research Shows

The evidence base differs by medicine and by how each one is administered. Ketamine stands apart because it has both decades of controlled research and published real-world data from at-home treatment. Other psychedelic medicines show promising trial results, but almost all of that evidence comes from single supervised doses in research or clinic settings, using different populations and rating scales. That makes the comparisons below directional rather than exact, and none of these other medicines is currently available for at-home or telemedicine use.

In Mindbloom's own peer-reviewed, real-world outcomes studies of at-home ketamine therapy, 89% of patients reported symptom improvement for depression and anxiety.⁵In a separate study on Mindbloom's subcutaneous protocol, 84.6% of PTSD patients achieved a clinically meaningful reduction in symptoms, measured on the PCL-5.

The other medicines show strong signals in their respective trials:

• MDMA (PTSD): In a phase 3 trial, 71% of participants no longer met the diagnostic criteria for PTSD after MDMA-assisted therapy, compared with 48% who received therapy with placebo.⁹
• Psilocybin (depression): A single 25 mg dose produced remission in roughly 30% of people with treatment-resistant depression at three weeks in a phase 2b trial. The program has since reported positive phase 3 results and holds FDA breakthrough therapy designation.¹⁰
• LSD (anxiety): A single dose of MM120, a form of LSD, produced a 65% response rate and a 48% remission rate at 12 weeks in generalized anxiety disorder, and also holds FDA breakthrough therapy designation.¹¹
• DMT (depression): A single dose of intravenous DMT produced a 57% remission rate at three months in major depressive disorder in an early phase 2a trial.¹²

What links these results is a pattern that differs from conventional care: where first-line antidepressants are taken daily and can take four to six weeks to work, these medicines often produce meaningful improvement after one or a few supervised sessions. The practical difference for patients today is access. Of all these options, only ketamine can be prescribed and taken at home under telemedicine, which is the focus of the sections that follow.

What Telemedicine Can and Cannot Do in Psychedelic Therapy

Several components of psychedelic therapy lend themselves to telemedicine delivery, though not every psychedelic medicine or element of in-person care can be replicated remotely.

For ketamine therapy specifically, telemedicine can support the full treatment arc from screening through integration. For other psychedelic medicines, telemedicine's role is currently limited to preparation and follow-up.

What telemedicine CAN do:

• Medical screening and eligibility evaluation: Licensed providers can conduct comprehensive health and psychiatric evaluations via video.
• Prescribing: Where state law permits, providers can prescribe ketamine through telemedicine and have it shipped to your home from a licensed pharmacy.
• Preparation: Providers and guides can prepare you for your session, covering what to expect, how to set up your environment, and safety planning.
• Integration and follow-up: Post-session integration, including coaching, group support, and medical check-ins, can be delivered effectively through telemedicine.

What telemedicine CANNOT do:

• Administer MDMA or psilocybin: Regulatory and safety requirements mandate on-site care settings for these substances.
• Replace in-session safety protocols: Even for at-home ketamine therapy, a peer treatment monitor is required to be physically present during every session. Telemedicine supports the care framework around the session, but the session itself requires a physical safety presence.
• Override state licensing requirements: Telemedicine prescribing laws vary by state, and not all states permit remote prescribing of controlled substances.

Remote delivery does not reduce the standard of medical rigor. When delivered with licensed-provider evaluation, a required peer treatment monitor, and follow-up care, telemedicine can preserve core safety and oversight elements of a clinically structured ketamine program while expanding access for people who cannot easily reach a clinic.

Which Psychedelic Treatments Can Be Delivered With Telemedicine Today

Ketamine is currently the only psychedelic-adjacent medicine that can be prescribed via telemedicine and administered at home in most U.S. states, while MDMA and psilocybin remain limited to in-person or regulated settings. The legal, regulatory, and medical requirements differ substantially by substance.

Ketamine-Assisted Therapy at Home

Among psychedelic-adjacent medicines, only ketamine can currently be prescribed via telemedicine and taken at home in most U.S. states.

A licensed prescriber evaluates you via video and prescribes ketamine if medically appropriate. The medicine is shipped from a licensed pharmacy. Sessions take place at home with a required peer treatment monitor present.

Your treating specialist and care team offer preparation before and integration support after each session. Ketamine is available in sublingual and subcutaneous formulations for at-home use. Because no other psychedelic medicine is available for remote prescribing and home administration in most states, at-home ketamine remains the most practical option for people seeking this type of care without clinic visits. Providers such as Mindbloom deliver this full model, from video-based screening through integration.

MDMA-Assisted Therapy in Care Settings

MDMA-assisted therapy cannot be delivered at home or through telemedicine. It is a protocol studied primarily for PTSD, involving multiple preparation and integration sessions around two to three MDMA dosing sessions that must take place on-site under direct medical supervision.

The FDA has not approved MDMA-assisted therapy as of this writing, and access is limited to research trials and expanded access programs. Only the preparation and integration sessions can be conducted remotely; the dosing sessions themselves always require physical presence at a licensed facility.

Psilocybin Therapy in Regulated Programs

Like MDMA, psilocybin therapy cannot be prescribed via telemedicine or taken at home under any current U.S. regulatory framework. It involves guided sessions with psilocybin mushrooms or synthetic psilocybin, which take place in person at a supervised service center or care setting.

Oregon and Colorado have created regulated frameworks for psilocybin services, and both require on-site attendance at licensed service centers. The FDA has granted breakthrough therapy designation for psilocybin for treatment-resistant depression, but no FDA approval exists yet.

Where Can You Get Psychedelic-Assisted Therapy?

Access to psychedelic-assisted therapy depends on which substance, what regulatory pathway, and where you live. Options range from research trials to state-regulated programs to telemedicine-based ketamine therapy.

• Clinical trials: MDMA and psilocybin are available through FDA-regulated research trials at select institutions. Enrollment criteria are strict, waitlists can be long, and geographic access is limited.
• State-regulated programs: Oregon and Colorado have legalized psilocybin services at licensed facilities. State programs require in-person attendance and are not covered by insurance.
• International retreats: Some people travel abroad for ayahuasca, psilocybin, or ibogaine retreats. Such retreats operate outside U.S. regulatory oversight and vary widely in care standards and safety protocols.
• IV ketamine clinics:IV ketamine infusions are available in many U.S. cities. In-clinic infusions require in-person visits, typically cost more per session, and may not include integration support.
• Telemedicine ketamine therapy: At-home psychecdelic therapy through telemedicine providers offers the broadest geographic access. Mindbloom is the largest provider of at-home ketamine therapy and the only one with peer-reviewed, real-world outcomes published for depression, anxiety, and PTSD.

For many people seeking psychedelic-assisted therapy today, telemedicine-based ketamine therapy is the most geographically available option, with published real-world outcomes data and no need for in-person clinic visits.

How Telemedicine Ketamine Therapy Works and What Safe Programs Include

Telemedicine ketamine therapy follows a clinically managed process. It mirrors the preparation, session, and integration model of clinic-based psychedelic therapy, adapted for remote delivery.

1. Online intake and eligibility screening: The process begins with a comprehensive health questionnaire. A licensed provider then conducts a video evaluation to review medical history, psychiatric history, current medications, and contraindications. Screening is designed to determine whether ketamine therapy is medically appropriate for an individual based on their health history, psychiatric profile, current medications, and overall risk factors.
2. Provider evaluation and treatment plan: If the prescribing physician determines you are medically appropriate, they develop a personalized care plan including dosing, session frequency, and goals. Ketamine is prescribed and shipped from a licensed pharmacy.
3. Preparation and session planning: Before the first session, you receive preparation materials and guidance on setting up your environment, including lighting, comfort, and minimizing distractions. A session monitor is identified and briefed on their role. As described above, a peer treatment monitor must be physically present during every session.
4. The at-home session with a safety plan: You take the prescribed ketamine at home with your peer treatment monitor present. Sessions typically last 60 to 90 minutes. A safety plan is in place that includes emergency contact protocols and access to emergency care.
5. Integration support and progress check-ins: After each session, you engage in integration activities such as journaling, reflection, and coaching sessions. Your care team conducts follow-up evaluations to monitor progress, adjust dosing if needed, and assess whether continued therapy is appropriate.

A safe program requires specific elements to protect your health.⁷

• Licensed medical oversight at every stage, not just prescribing
• Comprehensive eligibility screening that includes medical, psychiatric, and medication review
• Required peer treatment monitor (see safety protocols above)
• Defined preparation before the first session
• Integration support after each session, including coaching and group support
• Ongoing medical monitoring with dosage adjustments based on progress
• Published outcomes data, such as peer-reviewed studies showing 89% symptom improvement⁵ and serious adverse events in fewer than 0.1% of sessions¹

A program that skips any of these components omits core safeguards associated with safer, clinically structured at-home care.

How Mindbloom Delivers Protocol-Driven At-Home Psychedelic Therapy

Mindbloom operationalizes each of the components described above through a comprehensive care model. The Mindbloom care model has supported over 800,000 supervised sessions to date.

Medical Screening and Oversight

Mindbloom's licensed providers conduct video-based medical evaluations that include full medical and psychiatric history review, medication assessment, and contraindication screening. Your treating specialists continue to oversee your care throughout the program, adjusting the plan as needed based on progress and professional judgment. The evaluation is not a one-time prescribing interaction.

Preparation and Informed Consent

You receive preparation before your first session, including guidance on environment setup, what to expect during the experience, and a detailed safety plan. Mindbloom's guide coaching sessions provide one-on-one preparation support. Informed consent covers the off-label nature of ketamine prescribing, potential side effects, and the role of the peer treatment monitor.

Monitoring and Emergency Planning

As described above, a peer treatment monitor must be physically present during every session. You have access to on-call care throughout the session window. Your safety plan includes emergency contact protocols and clear instructions for your session monitor.

Integration Support and Follow-Up Care

Mindbloom's integration support includes one-on-one guide coaching, unlimited Group Integration Circles, and unlimited guide messaging. Follow-up consults evaluate progress and adjust the care plan.

Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a licensed physician conducts a comprehensive medical evaluation to confirm your eligibility and personalize your care plan.

Mindbloom's at-home ketamine therapy starts at $165 per session for a new client 18-session program, billed in monthly installments. Returning clients pay as little as $129 per session with an 18-session program.

Conclusion

You can access psychedelic therapy through telemedicine today, but the scope depends on the substance. Only ketamine, among psychedelic-adjacent medicines, is available for home administration through telemedicine in most U.S. states.

MDMA and psilocybin require supervised facility settings under current regulations. The quality of a telemedicine program depends on its care framework, including screening, preparation, in-session safety protocols, and integration support.

Not all providers deliver all of these components. When evaluating options, look for published outcomes data, licensed provider oversight at every stage, and a required peer treatment monitor during sessions. Mindbloom is built around all three, with peer-reviewed outcomes and more than 800,000 supervised sessions to date.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment.⁴ Schedule III Controlled Substance - DEA regulations apply.